• MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

    1 month ago - By News Medical

    MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma.
    Read more ...